HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Homozygous lamin A/C familial lipodystrophy R482Q mutation in autosomal recessive Emery Dreifuss muscular dystrophy.

Abstract
Autosomal recessive Emery Dreifuss muscular dystrophy (AR-EDMD) is rare, with few reports in the medical literature. We describe the first cases of AR-EDMD and autosomal dominant familial partial lipodystrophy (FPLD) in the Hutterite population resulting from homozygous or heterozygous R482Q mutations in the lamin A/C gene (LMNA). Heterozygosity for LMNA R482Q mutation causes FPLD, which is associated with increased risk of hyperlipidemia and hypertension. The overall carrier frequency of the R482Q mutation in Dariusleut and Leherleut Hutterites in Alberta was found to be 1.45%. Homozygosity for this mutation has not been previously reported and here resulted in a combination of generalized lipodystrophy and EDMD. Knowledge that the LMNA R482Q mutation is present in this population is important for genetic counseling, surveillance, and management of the associated disorders.
AuthorsKatie M Wiltshire, Robert A Hegele, A Micheil Innes, A Keith W Brownell
JournalNeuromuscular disorders : NMD (Neuromuscul Disord) Vol. 23 Issue 3 Pg. 265-8 (Mar 2013) ISSN: 1873-2364 [Electronic] England
PMID23313286 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier B.V. All rights reserved.
Chemical References
  • LMNA protein, human
  • Lamin Type A
Topics
  • Alberta
  • Child
  • Disease Progression
  • Female
  • Heterozygote
  • Humans
  • Lamin Type A (genetics)
  • Lipodystrophy, Familial Partial (genetics, pathology)
  • Male
  • Muscle, Skeletal (pathology)
  • Muscular Dystrophy, Emery-Dreifuss (genetics, pathology)
  • Mutation
  • Pedigree
  • Phenotype

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: